Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Last updated: December 28, 2023
Sponsor: Poitiers University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Leukemia

Lymphoproliferative Disorders

Waldenstrom Macroglobulinemia

Treatment

Venetoclax

Clinical Study ID

NCT06200220
WAVE
  • Ages > 18
  • All Genders

Study Summary

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Waldenstrom's macroglobulinemia
  • Treatment with Venetoclax
  • Non opposition

Exclusion

Exclusion Criteria: none

Study Design

Total Participants: 45
Treatment Group(s): 1
Primary Treatment: Venetoclax
Phase:
Study Start date:
December 28, 2023
Estimated Completion Date:
December 01, 2025

Connect with a study center

  • CHU Poitiers

    Poitiers, 86000
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.